UBS Downgrades Pharmasset (VRUS) to Neutral
More News related to VRUS
- InterMune (ITMN) Higher Following INFORM-1 Trial Data
- Baird Maintains an 'Outperform' on Pharmasset (VRUS); Year Ahead is Catalyst-Rich
- INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
- INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
- Pharmasset to Webcast an Investor Event from the AASLD Meeting
UBS downgrades Pharmasset (Nasdaq: VRUS) from Buy to Neutral.
Traders are shrugging off the UBS downgrade today, and buying shares of Pharmasset. The stock most recently traded at $10.49, up 3%.
Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections.
Related Categories
DowngradesStocks Mentioned
+1.30Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
